Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00804973 · ClinicalTrials.gov registry record · Phase 2
Study in Participants With Acute Migraines Headaches
A Phase 2 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT00804973 is a Phase 2 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 120 participants.
The verdict
NCT00804973, a Phase 2 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
This is a Phase 2, multicenter, randomized, double-blind, placebo and active comparator-controlled study of LY2590443 in approximately 200 participants with migraines.
Interventions
- DRUG Placebo capsule
- DRUG Placebo injection
- DRUG Sumatriptan
- DRUG LY2590443
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2008-11 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00804973
The ClinicalTrials.gov registry entry for NCT00804973 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo capsule is the first listed.
NCT00804973 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00804973 about?
NCT00804973 is a clinical study titled "Study in Participants With Acute Migraines Headaches". This is a Phase 2, multicenter, randomized, double-blind, placebo and active comparator-controlled study of LY2590443 in approximately 200 participants with migraines.
What is the current status of trial NCT00804973?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2008-11. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00804973?
The interventions under investigation include: Placebo capsule (DRUG), Placebo injection (DRUG), Sumatriptan (DRUG), LY2590443 (DRUG).
Who is sponsoring clinical trial NCT00804973?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.